Androgenetic Alopecia Therapeutics Pipeline Analysis by Stages, Drug Class, Company Profile, Phase of Development, Clinical Trial & Discovery Stage Insights

Androgenetic Alopecia Therapeutics – Competitive Landscape, Epidemiology Forecast, and Pipeline Analysis, 2019 published by Pharma Proff, androgenetic alopecia therapeutics currently exhibits a proliferating pipeline with 15+ therapeutic candidates.

Androgenetic Alopecia Therapeutics Pipeline Insights

Androgenetic alopecia is a genetic disorder of patterned hair loss that affects both men and women. The disorder shortens hair growth cycle due to excess of androgen, which eventually delays hair growth. Some of the major symptoms include gradual recession of frontal hairline, increased hair fall, bitemporal recession of hair, and thinning of the hair. The symptoms start appearing at the age of 20 and are seen to be prominent in people aged 40 years and above. The disorder leads to hair thinning near crown region, and maybe caused due to various genetic as well as environmental factors. The disorder can also occur due to hormonal imbalance, improper functioning of androgen hormones, poor diet, and excessive smoking.

Request to Get the Sample Pages at: 

Insights into Pipeline Segments

According to the research, many drugs being developed for androgenetic alopecia, which are administered topically. It has been found that topical route of administration is easy to use, non-invasive, and ensures high level of patient satisfaction.

Positive Clinical Trial Results are Expected to Drive Androgenetic Alopecia Therapeutics Pipeline

There are several companies which have shown positive results of clinical trials. For instance, in February 2019, Cassiopea SpA announced effective result of Phase II clinical trial of Breezula for treatment of androgenetic alopecia.

Browse Detailed Report at: https://www.pharmaproff.com/report/androgenic-alopecia-therapeutics-pipeline-analysis

Technological Advancements Play a Pivotal Role in Androgenetic Alopecia Therapeutics Development

It has been observed that many pharmaceutical companies are developing new and improved technologies for the development of androgenetic alopecia therapeutics. These technologies play an important role in the drug development by helping the companies to develop more specific and effective targeted therapies. For instance, RepliCel Life Sciences is using its proprietary cell therapy technology to develop therapeutic candidates for pattern baldness and other disorders. It utilizes dermal sheath cup cells, which induce the growth of cells in the area of baldness.

Samumed LLC, Brickell Biotech Inc., Aclaris Therapeutics Inc., Cassiopea S.p.A, Kerastem Technologies LLC, Almirall S.A., and RepliCel Life Sciences are the major players involved in the development of drug candidates for the treatment of androgenetic alopecia.